Khan Reviews Later-Line Therapy Options for DLBCL With Subgroup ConsiderationsJuly 10th 2022
During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.
Clinical Commentary: Addressing Challenges in Unresectable HCC and Adding Lenvatinib to Therapy SequencingJuly 9th 2022
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, discussed therapeutic sequencing for patients with unresectable hepatocellular carcinoma and the use of lenvatinib versus sorafenib.
Roundtable Discussion: Barata Explores Second- and Third-Line Options for Recurrent RCCJuly 8th 2022
During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed the case of a patient with clear cell renal cell carcinoma who progressed following frontline treatment with axitinib/pembrolizumab.
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPCJuly 5th 2022
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
Burger Details the Data to Help Choose Treatment in Chronic Lymphocytic LeukemiaJuly 3rd 2022
During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.
Chao Discusses Stratifying and Treating Patients With Graft-Vs-Host DiseaseJune 27th 2022
During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.
Lee and McGregor Discuss Methods to Integrate New Approaches in RCC TreatmentJune 25th 2022
During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.
Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLCJune 22nd 2022
During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.
Roundtable Discussion: Rao Looks At Multiple Scenarios That Highlight Single-Agent Treatment in Metastatic TNBCJune 21st 2022
During a Targeted Oncology case-based roundtable event, Ruta D. Rao, MD, discussed the case of a patient with metastatic triple-negative breast cancer who progressed following frontline adjuvant ddAC-paclitaxel.
Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCLJune 20th 2022
During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.
Roundtable Discussion: Dowlati Breaks Down Updated Treatment Data in SCLCJune 20th 2022
During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed with participants the results of the CASPIAN and IMpower 133 trials of new regimens for extensive-stage small cell lung cancer.
Evaluating First-Line Treatment Options for Metastatic ccRCCJune 19th 2022
During a Targeted Oncology case-based roundtable event, Chandler Park, MD, discussed the preferred first-line treatment options including tyrosine kinase inhibitor/immunotherapy combinations for metastatic clear cell renal cell carcinoma.